BCI Clinical Trials Neurodegenerative
Overview
flowchart TD
BCI["BCI Technology"]
TRIALS["Clinical Trials"]
BCI -->|"enhances"| TRIALS
style BCI fill:#4fc3f7,stroke:#333,color:#000
style TRIALS fill:#81c784,stroke:#333,color:#000
This page provides a comprehensive overview of clinical trials investigating brain-computer interface (BCI) technologies for neurodegenerative diseases. BCI-based interventions represent a promising therapeutic approach["@clinicaltrialsgov"] for conditions including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [stroke](/diseases/stroke)-related neurological deficits.
Active Clinical Trials
[Parkinson's Disease](/diseases/parkinsons-disease) | Trial Name | Device/Intervention | Phase | Status | NCT Number |
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) ...
BCI Clinical Trials Neurodegenerative
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive overview of clinical trials investigating brain-computer interface (BCI) technologies for neurodegenerative diseases. BCI-based interventions represent a promising therapeutic approach["@clinicaltrialsgov"] for conditions including [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [stroke](/diseases/stroke)-related neurological deficits.
Active Clinical Trials
[Parkinson's Disease](/diseases/parkinsons-disease) | Trial Name | Device/Intervention | Phase | Status | NCT Number |
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) | Trial Name | Device/Intervention | Phase | Status | NCT Number |
[Stroke](/diseases/stroke) Rehabilitation | Trial Name | Device/Intervention | Phase | Status | NCT Number |
Epilepsy | Trial Name | Device/Intervention | Phase | Status | NCT Number |
Trial Phases Explained
Phase 1
Primary Goal : Safety and tolerabilityParticipants : Small group (10-50)Duration : Several monthsFocus : Identify adverse effects, determine safe dosage rangePhase 2
Primary Goal : Efficacy and side effectsParticipants : Larger group (100-300)Duration : Several months to yearsFocus : Compare treated vs. control groupsPhase 3
Primary Goal : Confirm efficacyParticipants : Large group (1,000-3,000)Duration : 1-4 yearsFocus : Monitor adverse reactions, compare to standard treatmentsPhase 4 (Post-Market)
Primary Goal : Long-term safetyParticipants : Large populationsDuration : OngoingFocus : Long-term effects, cost-effectivenessKey Inclusion Criteria
Typical Requirements for BCI Trials
Age : 18-75 years (varies by trial)Diagnosis : Confirmed neurodegenerative conditionDisease Severity : Moderate to severe impairmentCognitive Function : Able to provide informed consentNo Contraindications : No MRI incompatibilities, no active infections
Common Exclusion Criteria
Psychiatric Disorders : Active severe depression or psychosisCognitive Impairment : MMSE score below thresholdSeizure History : Active epilepsy (for some trials)Metal Implants : MRI-incompatible devicesPregnancy : Current pregnancy or planning pregnancy
Outcome Measures
Primary Endpoints
Communication Speed : Words per minute (for communication BCIs)Motor Function : Fugl-Meyer Assessment, Motor Assessment ScaleQuality of Life : EQ-5D, SF-36, disease-specific scalesAdverse Events : Frequency and severity of complicationsSecondary Endpoints
Neural Signal Quality : Signal-to-noise ratio, classification accuracyDevice Reliability : Uptime, maintenance requirementsUser Satisfaction : System Usability Scale, device preferenceLong-term Outcomes : 1-5 year follow-up measuresRegulatory Status
FDA Breakthrough Device Designations | Company | Device | Year | Indication |
CE Mark (European Union)
Synchron Stentrode: CE Marked (2022)
g.tec recovery: CE Marked (2021)
MindMaze: CE Marked (2020)
Leading Research Centers
United States
Stanford University : BrainGate consortiumUniversity of Pittsburgh : Neural engineering labUCLA : Neural computation labMassachusetts General Hospital : Clinical trialsEurope
University of Tübingen : BCI research (Germany)Charité Berlin : Neurotechnology (Germany)University of Oxford : Neural interface research (UK)Asia
Tokyo University : RIKEN BCI program (Japan)Tsinghua University : Neural engineering (China)Future Trial Directions
Anticipated Trials 2026-2028
Memory Prosthetic BCI : Trials for Alzheimer's-related memory impairmentBidirectional Neural Interfaces : Reading and writing to neural tissueFully Implantable Systems : No external hardware requirementsPersonalized Decoding : AI-based individual optimization
Emerging Indications
Huntington's Disease : Motor and cognitive symptom managementMultiple Sclerosis : Fatigue management and motor recoveryTraumatic Brain Injury : Cognitive rehabilitationChronic Pain : Neuromodulation for pain managementCross-References
[Brain-Computer Interface Technologies](/technologies/bci-index) — Main BCI technology index
[Neuralink](/companies/neuralink) — Neuralink company profile
[Synchron](/companies/synchron) — Synchron company profile
[Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment) — PD treatment options
[ALS Therapeutics](/therapeutics/als-therapeutics) — ALS treatment options
[Stroke Rehabilitation](/therapeutics/stroke-rehabilitation) — Stroke recovery therapies
[Closed-Loop Neuromodulation](/technologies/closed-loop-neuromodulation) — Adaptive stimulation technology
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, ClinicalTrials.gov - Brain-Computer Interface Studies (n.d.)
Unknown, FDA Breakthrough Device Program (n.d.)
Pathway Diagram The following diagram shows the key molecular relationships involving BCI Clinical Trials for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description